Daiichi Sankyo: Neoplasms trials

The registry lists 25 Neoplasms studies with Daiichi Sankyo as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 23Phase 2 2Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial CancerRecruitingNCT07022483Phase 3
• Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedNCT03383692Phase 1Results posted
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results posted
• Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsCompletedNCT02564900Phase 1Results posted
• Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedNCT02371369Phase 3Results posted
• Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT01525602Phase 1Results posted
• Safety Study of PLX108-01 in Patients With Solid TumorsCompletedNCT01004861Phase 1Results posted
• A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic AlterationsActive, not recruitingNCT06644768Phase 1/2
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant TumorsActive, not recruitingNCT04145622Phase 1/2
• U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerActive, not recruitingNCT03260491Phase 1
• Study of DS-1123a in Advanced Solid TumoursCompletedNCT02690337Phase 1
• Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant TumorsCompletedNCT02675491Phase 1
• A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell TumorTerminatedNCT02673736Phase 1
• Open Label Study of DS-5573aTerminatedNCT02192567Phase 1
• Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentCompletedNCT02150733Phase 1
• Phase 1 Study of DS-8895a in Subjects With Advanced Solid TumorsCompletedNCT02004717Phase 1
• Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid TumorsTerminatedNCT01804530Phase 1
• Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant TumorsCompletedNCT01290471Phase 1
• Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid TumorsCompletedNCT01149720Phase 1
• Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid TumorsCompletedNCT01049893Phase 1
• Phase I Study of U3P1287/01, Including Patients With Advanced Solid TumorsCompletedNCT00730470Phase 1
• Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)CompletedNCT00320827Phase 1
• DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00077077Phase 1
• Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid TumorsWithdrawnNCT00072228Phase 1
• DX-8951f in Treating Children With Advanced Solid Tumors or LymphomasCompletedNCT00004212Phase 1